Chylomicron Change
Introduction
Chylomicrons are large lipoprotein particles formed in the intestines after a meal, primarily responsible for transporting dietary fats (triglycerides and cholesterol) from the digestive system to various tissues throughout the body, including the liver, muscles, and adipose tissue. These particles are essential for the absorption and distribution of dietary lipids, playing a critical role in energy storage and cellular function. The term "chylomicron change" refers to variations in the levels, composition, or metabolic processing of these particles, which can have significant physiological consequences.
Biological Basis
The formation and metabolism of chylomicrons are complex processes involving several enzymes, apolipoproteins, and receptors. After dietary fats are absorbed by intestinal cells, they are re-esterified into triglycerides and packaged with cholesterol, phospholipids, and apolipoproteins (such as apolipoprotein B-48, APOB48) to form nascent chylomicrons. These nascent particles are then secreted into the lymphatic system and eventually enter the bloodstream. In circulation, chylomicrons acquire additional apolipoproteins (like apolipoprotein C-II, APOC2, and apolipoprotein E, APOE) from high-density lipoproteins (HDL). The enzyme lipoprotein lipase (LPL), located on the surface of capillary endothelial cells, hydrolyzes the triglycerides within chylomicrons, releasing fatty acids for tissue uptake. As triglycerides are removed, chylomicrons shrink, becoming chylomicron remnants, which are then cleared from the circulation by the liver via receptors that recognize APOE. Genetic variations in genes encoding these components, such as APOC2, APOE, or LPL, can influence the efficiency of chylomicron metabolism and lead to changes in their circulating levels or composition.
Clinical Relevance
Alterations in chylomicron metabolism are clinically relevant due to their association with various health conditions. Elevated levels of chylomicrons and their remnants in the blood, a condition known as postprandial hyperlipidemia, are a significant risk factor for cardiovascular diseases, including atherosclerosis. This is because remnant particles can be atherogenic, contributing to plaque formation in arteries. Severe elevations in triglycerides, often due to impaired chylomicron clearance, can also lead to acute pancreatitis, a serious and potentially life-threatening inflammatory condition of the pancreas. Furthermore, genetic predispositions influencing chylomicron metabolism can contribute to familial forms of hypertriglyceridemia, which require careful management. Research has identified genetic loci associated with plasma triglycerides, such as variation in MLXIPL, which highlights the genetic underpinnings of lipid metabolism. [1]
Social Importance
Understanding "chylomicron change" has broad social importance given the global prevalence of metabolic disorders and cardiovascular diseases. Dietary habits, particularly the consumption of high-fat meals, significantly impact chylomicron levels, making lifestyle interventions crucial for managing related health risks. Genetic insights into chylomicron metabolism offer opportunities for personalized medicine, allowing for targeted screening and interventions for individuals at higher genetic risk. Public health initiatives aimed at promoting healthy diets and regular physical activity can mitigate the impact of adverse chylomicron changes on population health. The interplay between genetics, diet, and lifestyle in influencing chylomicron metabolism underscores its importance in preventive medicine and chronic disease management.
Methodological and Statistical Constraints
Even with meta-analyses, studies investigating complex traits like chylomicron dynamics can be limited by statistical power to detect variants with small effect sizes. Initial discoveries in genome-wide association studies (GWAS) for blood lipid phenotypes sometimes report inflated effect sizes, necessitating rigorous replication in independent cohorts to ensure robustness and prevent false positives. [2] The collective sample sizes, while often large in meta-analyses, may still be insufficient to fully elucidate the polygenic architecture underlying subtle chylomicron changes or to identify rarer variants contributing to the trait.
The integration of data from multiple cohorts, as seen in meta-analyses, introduces potential heterogeneity in study designs and methodologies. [3] Differences in participant recruitment, age ranges, health status, and fasting protocols across studies could introduce systematic biases, affecting the combined estimates for chylomicron changes. This variability can obscure true genetic associations or lead to inconsistent findings, making it challenging to draw definitive conclusions about the precise genetic determinants of chylomicron metabolism.
Phenotypic Characterization and Generalizability
The precise definition and measurement of "chylomicron change" pose a significant limitation. While studies often measure broad "blood lipid phenotypes" or "lipid fractions" [3] the specific quantification of chylomicrons and their dynamic changes can vary. Methodological differences in lipid assays, timing of blood draws relative to meals (chylomicrons are postprandial), and the specific components of chylomicrons measured (e.g., total chylomicron concentration versus specific lipid content) can impact the comparability and interpretation of genetic associations. Inconsistent phenotyping can dilute true genetic signals or introduce noise.
The generalizability of findings concerning chylomicron change is potentially constrained by the ancestral composition of the study populations. Many large-scale genetic studies, including those contributing to meta-analyses on lipid phenotypes, have historically overrepresented individuals of European descent. [2] This demographic imbalance can limit the applicability of identified genetic associations to other ancestral groups, where allele frequencies, linkage disequilibrium patterns, and environmental exposures may differ significantly, potentially leading to varied genetic effects on chylomicron metabolism.
Environmental Confounding and Unexplained Heritability
Chylomicron metabolism is highly influenced by environmental factors such as diet, physical activity, and medication use. The inability to fully account for these non-genetic confounders and potential gene-environment interactions presents a substantial limitation. [3] For instance, dietary fat intake directly impacts chylomicron production and clearance, and genetic predispositions might only manifest under specific dietary conditions. Without comprehensive environmental data and robust statistical models to incorporate these interactions, the genetic variants identified may represent only a fraction of the true biological drivers, or their effects may be masked or exaggerated.
Despite the identification of numerous genetic loci associated with lipid traits, a significant portion of the heritability for complex traits like chylomicron change remains unexplained, a phenomenon often termed "missing heritability". [2] This gap suggests that current GWAS approaches might not fully capture the contributions of rare variants, structural variations, or complex epistatic interactions. Furthermore, the functional mechanisms by which many identified genetic variants influence chylomicron metabolism are often not fully elucidated, representing a crucial knowledge gap that requires further mechanistic and functional studies beyond statistical association.
Variants
The gene C5orf67 (Chromosome 5 open reading frame 67) encodes a protein whose precise cellular functions are still under investigation, but it is recognized for its potential involvement in various metabolic pathways and cellular processes. Genetic variations within or near C5orf67, such as the single nucleotide polymorphism (SNP) rs467022, have drawn attention due to their possible influence on lipid metabolism and related health outcomes. While the specific mechanism by which rs467022 impacts C5orf67 activity is an area of ongoing research, it is hypothesized that such variants can affect gene expression, protein stability, or interactions with other molecules crucial for lipid regulation. [4] Understanding these genetic influences is important for unraveling the complex genetic architecture of lipid traits, which are often polygenic, involving contributions from multiple genes and environmental factors. [5]
Chylomicrons are large lipoprotein particles responsible for transporting dietary triglycerides and cholesterol from the small intestine to peripheral tissues. Variants like rs467022 within or near C5orf67 may influence the efficiency of chylomicron synthesis, assembly, secretion, or clearance from the bloodstream, thereby affecting circulating chylomicron levels. For instance, an altered C5orf67 function could impact enzymes or structural proteins involved in chylomicron metabolism, leading to either an accumulation or more rapid removal of these particles. [6] Proper chylomicron metabolism is critical for maintaining healthy lipid profiles, as imbalances can contribute to conditions like postprandial hyperlipidemia, a state of elevated blood lipids after a meal, which is a risk factor for cardiovascular disease. [5]
Variations affecting chylomicron metabolism, such as rs467022 in C5orf67, have broader implications for overall cardiovascular health. Dysregulation of chylomicron levels can contribute to dyslipidemia, a condition characterized by abnormal levels of lipids (fats) in the blood, including high triglycerides and low-density lipoprotein cholesterol, and low high-density lipoprotein cholesterol. [7] These altered lipid profiles are significant risk factors for the development of atherosclerosis and coronary artery disease. Therefore, identifying and characterizing variants like rs467022 helps to clarify the genetic underpinnings of these common metabolic disorders and may ultimately contribute to personalized prevention and treatment strategies for related conditions. [5]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs467022 | C5orf67 | esterified cholesterol change measurement, blood VLDL cholesterol amount lipid change measurement, blood VLDL cholesterol amount, chylomicron amount chylomicron change measurement triglyceride change measurement, blood VLDL cholesterol amount, chylomicron amount Abnormality of the skeletal system |
Causes of Chylomicron Change
Chylomicrons, as key transporters of dietary fats, undergo dynamic changes influenced by a confluence of genetic predispositions, environmental factors, and the overall physiological state of an individual. These changes, often reflected in altered serum lipid levels, are critical for understanding metabolic health and disease risk.
Genetic Predisposition to Altered Chylomicron Metabolism
Genetic factors play a substantial role in determining an individual's chylomicron metabolism and associated lipid profiles. Numerous inherited variants have been identified through genome-wide association studies (GWAS) that contribute to variations in serum triglyceride, LDL cholesterol, and HDL cholesterol levels, all of which are intrinsically linked to chylomicron synthesis, processing, and clearance. For instance, single nucleotide polymorphisms (SNPs) within the APOA1/APOC3/APOA5 gene cluster, such as rs6589566 and rs12286037, are strongly associated with serum triglyceride levels, reflecting their role in lipoprotein lipase activity and chylomicron catabolism . [4], [6] Similarly, variants in GCKR (rs780094) and LPL (rs10503669) are also recognized for their impact on triglycerides, influencing the regulation of glucokinase and the breakdown of triglycerides in chylomicrons, respectively . [4], [6]
Beyond these specific genes, chylomicron change is often a characteristic of polygenic dyslipidemia, where multiple independent common alleles at various loci collectively contribute to the trait variation. Studies have identified over 30 such loci, including HMGCR (e.g., rs7703051, rs12654264, rs3846663 for LDL-C), CETP, LIPC, the APOE-APOC cluster (rs4420638), LDLR (rs6511720), APOB (rs562338), CELSR2-PSRC1-SORT1 (rs599839), NCAN/CILP2 (rs16996148), MLXIPL, GALNT2, and TRIB1, which influence the synthesis, transport, and degradation of various lipoproteins, thereby impacting chylomicron dynamics . [5], [6], [7], [8], [9], [10] The cumulative effect of these genetic variants can lead to a stepwise increase or decrease in lipoprotein concentrations, underscoring the complex genetic architecture underlying chylomicron metabolism. [5]
Environmental and Lifestyle Influences on Chylomicron Dynamics
Environmental and lifestyle factors are significant modulators of chylomicron change, primarily through their impact on diet and exposure to external agents. Dietary composition, particularly the intake of fats, directly influences the amount and type of chylomicrons produced in the intestine. While the provided research focuses on genetic predispositions, the emphasis on "fasting lipid concentrations" and the exclusion of individuals on "lipid-lowering therapy" in studies implicitly highlights the role of diet and medication in altering chylomicron-related lipid levels . [5]
Furthermore, pharmacotherapy, such as lipid-lowering drugs like statins, profoundly affects lipid metabolism. These medications are designed to reduce circulating cholesterol and triglyceride levels, directly influencing the pool of lipids available for chylomicron assembly and the clearance of chylomicron remnants . [5], [8] The efficacy of such treatments can vary among individuals, partly due to genetic factors, emphasizing the complex interplay between environment and an individual's genetic makeup.
Complex Interactions and Physiological Modulators
The changes observed in chylomicron metabolism are frequently shaped by complex interactions between genetic predisposition and various physiological and environmental factors. A notable example of gene-environment interaction is the varying response to statin therapy, where specific variants in genes like HMGCR have been associated with racial differences in the reduction of low-density lipoprotein cholesterol levels following simvastatin treatment. [8] This suggests that an individual's genetic background can modify how they respond to environmental interventions or exposures, including medication.
Beyond gene-environment interactions, other physiological factors contribute to chylomicron changes. Comorbidities, such as diabetes status, are recognized as significant contributors to dyslipidemia, directly impacting glucose and lipid homeostasis, which in turn affects chylomicron synthesis and clearance . [5] Additionally, age and sex are consistently identified as important variables influencing lipid profiles; studies frequently adjust for "age, age2, and gender" when analyzing lipid concentrations, indicating their established role in modulating chylomicron dynamics over time and across biological sexes . [5]
Chylomicron Metabolism: Synthesis, Transport, and Fate
Chylomicrons are large lipoprotein particles primarily responsible for transporting dietary fats, mainly triglycerides, from the intestine to various tissues throughout the body. Their journey begins in the intestinal enterocytes, where absorbed fatty acids and monoglycerides are re-esterified into triglycerides and packaged with cholesterol and apolipoproteins, notably ApoB-48, to form nascent chylomicrons. These nascent particles are then secreted into the lymphatic system before entering the bloodstream, where they acquire additional apolipoproteins like ApoC-II and ApoE from high-density lipoproteins (HDL). In the capillaries of muscle and adipose tissue, the enzyme lipoprotein lipase (LPL), activated by ApoC-II, hydrolyzes the triglycerides within chylomicrons, releasing fatty acids for energy or storage. As triglycerides are removed, chylomicrons shrink and become chylomicron remnants, which are then cleared from circulation by the liver through receptor-mediated endocytosis, a process facilitated by ApoE. This intricate metabolic pathway ensures efficient distribution of dietary lipids and is crucial for maintaining energy balance and structural integrity.
Genetic Influences on Lipid Processing
Genetic variations significantly impact an individual's lipid profile and the efficiency of chylomicron metabolism. Specific genes and their regulatory elements dictate the synthesis, processing, and clearance of these vital lipid carriers. For example, a genome-wide scan identified variations in the gene MLXIPL (also known as ChREBP) that are associated with plasma triglyceride levels. [1] MLXIPL functions as a transcription factor, playing a key role in regulating the expression of genes involved in de novo lipogenesis—the synthesis of fatty acids and triglycerides—primarily within the liver. Genetic alterations affecting MLXIPL activity can therefore modulate hepatic lipid production, which in turn influences the overall lipid burden and the processing capacity for dietary triglycerides carried by chylomicrons. Furthermore, common genetic variations near MC4R have been linked to waist circumference and insulin resistance [1] both of which are critical determinants of metabolic health and can indirectly influence lipid metabolism by affecting pathways that regulate chylomicron processing.
Hormonal Regulation and Metabolic Interconnections
The precise control of chylomicron metabolism is deeply integrated within broader hormonal and metabolic signaling networks that ensure nutrient homeostasis. Hormones such as insulin are central regulators, promoting the storage of triglycerides in adipose tissue by stimulating lipoprotein lipase activity and suppressing hepatic glucose production and lipolysis. Disruptions in insulin signaling, particularly insulin resistance, can impair these crucial processes, leading to elevated postprandial triglycerides and reduced chylomicron clearance, thereby contributing to dyslipidemia. The liver's capacity to process lipids and respond to metabolic cues is also paramount, with its gene expression patterns being subject to a complex genetic architecture [11] which profoundly influences its role in overall lipid homeostasis and its ability to handle the influx of dietary fats. These regulatory networks involve numerous transcription factors and signaling pathways that coordinate nutrient sensing with lipid synthesis and breakdown, ensuring a balanced metabolic state.
Pathophysiological Implications of Dysregulated Chylomicrons
Alterations in chylomicron metabolism can have significant pathophysiological consequences, contributing to various metabolic disorders and disease mechanisms. Persistent elevation of chylomicrons and their remnants in the bloodstream, especially after meals, characterizes postprandial hyperlipidemia, a recognized risk factor for cardiovascular disease. This homeostatic disruption can lead to the accumulation of atherogenic remnant particles in the arterial wall, initiating or exacerbating atherosclerotic plaque formation. Conditions such as insulin resistance, often associated with genetic factors like those near MC4R [1] exacerbate these issues by impairing LPL activity and hepatic remnant clearance, further contributing to a pro-atherogenic lipid profile and systemic metabolic dysfunction. These disruptions highlight how imbalances in the processing of dietary fats can have far-reaching effects on cardiovascular health and overall metabolic well-being.
Metabolic Pathways Governing Lipid Dynamics
The synthesis, transport, and catabolism of lipids are tightly regulated processes that significantly influence chylomicron dynamics. Key enzymes and proteins orchestrate the flux of fatty acids and cholesterol through various pathways. For instance, MLXIPL (also known as ChREBP) plays a crucial role by binding to and activating specific motifs in the promoters of genes involved in triglyceride synthesis, thereby directly impacting the production of these lipid components. [6] Similarly, ANGPTL3 and ANGPTL4 are major regulators of lipid metabolism, with ANGPTL3 functioning as a potent hyperlipidemia-inducing factor and an inhibitor of lipoprotein lipase (LPL), an enzyme critical for triglyceride hydrolysis. [12] The mevalonate pathway, responsible for cholesterol biosynthesis, involves enzymes like MVK (mevalonate kinase), which catalyzes an early step in this process. [6]
Catabolic pathways are equally vital for maintaining lipid homeostasis. The apolipoprotein APOA5, often found in a cluster with APOA1, APOA4, and APOC3, is strongly associated with plasma triglyceride levels, indicating its role in the clearance or processing of triglyceride-rich lipoproteins. [13] Dysregulation in these catabolic processes can lead to conditions like hypertriglyceridemia, as observed in models with increased APOC3 and reduced APOE on lipoprotein particles, leading to a diminished very low-density lipoprotein fractional catabolic rate. [14] Furthermore, the Adiponutrin gene (PNPLA2), expressed in adipose tissue, is regulated by insulin and glucose, influencing lipid storage and breakdown, and its variation has been linked to obesity. [15]
Genetic and Transcriptional Regulation of Lipid Metabolism
Gene regulation plays a fundamental role in controlling the expression of proteins involved in lipid metabolism, thereby impacting chylomicron formation and clearance. Transcription factors such as HNF1A and HNF4A are essential for maintaining hepatic gene expression and overall lipid homeostasis. [16] HNF1A, for instance, is a critical regulator of bile acid and plasma cholesterol metabolism and is implicated in the pathophysiology of maturity-onset diabetes of the young (MODY2). [17] Another key regulatory element is SREBP2, a transcription factor that controls the expression of genes involved in isoprenoid and cholesterol metabolism, including MVK and MMAB. [18]
Genetic variations, such as single nucleotide polymorphisms (SNPs), can profoundly affect these regulatory mechanisms. A common polymorphism in the GCKR (glucokinase regulator) gene, for example, is associated with elevated fasting serum triacylglycerol levels and influences insulin sensitivity, highlighting its impact on metabolic flux control. [19] Beyond transcriptional control, post-transcriptional mechanisms like alternative splicing also contribute to metabolic regulation; common SNPs in the HMGCR gene, which encodes the rate-limiting enzyme in cholesterol synthesis, have been shown to affect the alternative splicing of its exon 13, influencing enzyme activity and subsequent cholesterol levels. [8]
Signaling Cascades and Post-Translational Control
Cellular signaling pathways and post-translational modifications are critical for dynamically adjusting chylomicron metabolism in response to physiological cues. While specific receptor activation details for chylomicron processing are not extensively delineated, the broader context of lipid metabolism involves intricate signaling networks. For instance, the MAPK (mitogen-activated protein kinase) pathway is a general signaling cascade that can be activated in various tissues, including skeletal muscle, influencing metabolic responses. [20]
Post-translational modifications provide a rapid and reversible means of regulating protein function without altering gene expression. Glycosylation, mediated by enzymes like GALNT2 (a widely expressed glycosyltransferase), could potentially modify lipoproteins or their receptors, thereby altering their recognition, stability, or activity in chylomicron metabolism. [6] Furthermore, changes in protein structure due to amino acid exchanges can have significant functional consequences, as seen with LCAT (lecithin-cholesterol acyltransferase), where a specific amino acid change leads to the selective loss of its alpha-activity, contributing to conditions like fish eye disease. [21]
Systems-Level Integration and Disease Mechanisms
The regulation of chylomicron dynamics is not isolated but is part of a highly integrated metabolic network where various pathways crosstalk and interact. Genetic variants often influence multiple lipid parameters, reflecting the interconnected nature of lipid metabolism; for instance, loci within the APOA cluster (A1/A4/A5/C3) are associated with broad effects on lipid levels. [13] Genome-wide association network analyses (GWANA) leverage such pathway information to identify biological pathways enriched among highly associated genes, providing a systems-level understanding of genetic influences on metabolism. [13] This hierarchical regulation ensures robust control over lipid homeostasis, but can also lead to complex dysregulation in disease states.
Pathway dysregulation is a hallmark of many metabolic disorders, with significant implications for chylomicron change. Conditions like hypertriglyceridemia and dyslipidemia are often linked to genetic variations affecting key regulators such as LPL or ANGPTL3. [22] Compensatory mechanisms can also emerge in disease; for example, in cholestatic hypercholesterolemia, the presence of lipoprotein-X can influence the activity of HMGCR, potentially altering cholesterol synthesis. [23] Understanding these integrated pathways and their dysregulation provides critical insights for identifying therapeutic targets, such as the hepatic cholesterol transporter ABCG8, which has been identified as a susceptibility factor for gallstone disease [24] or enzymes like HMGCR in cholesterol management.
Genetic Regulation of Chylomicron-Related Lipids
Genetic variations play a crucial role in determining plasma lipid levels, including triglycerides, which are primary components of chylomicrons. A genome-wide scan identified specific variations in the MLXIPL gene that are significantly associated with plasma triglyceride concentrations. [1] Understanding these genetic influences offers foundational insight into the underlying mechanisms of chylomicron metabolism. This knowledge contributes to a more precise risk assessment by pinpointing genetic factors that predispose individuals to altered chylomicron levels.
Clinical Applications for Risk Stratification and Monitoring
Changes in chylomicron levels, often reflected by plasma triglyceride concentrations, serve as important indicators for risk stratification and monitoring strategies in patient care. The identification of genetic variations, such as those in MLXIPL affecting triglycerides, allows for the identification of high-risk individuals who may be predisposed to elevated chylomicron levels. [1] Such genetic insights can guide personalized medicine approaches, enabling clinicians to tailor prevention strategies and implement targeted monitoring protocols. This proactive approach can help manage the long-term health implications associated with altered chylomicron metabolism.
Prognostic Value and Therapeutic Guidance
The prognostic value of chylomicron changes, particularly those influenced by genetic factors like MLXIPL variations affecting plasma triglycerides, is significant for predicting disease progression and outcomes. [1] Monitoring these genetically influenced lipid parameters can help assess treatment response and guide therapeutic selection. For example, knowing a patient's genetic predisposition to high triglycerides could inform the choice of specific lipid-lowering interventions. This leads to more effective treatment strategies and improved patient care by addressing the root cause of altered chylomicron levels.
References
[1] Kooner, J.S., Chambers, J.C., Aguilar-Salinas, C.A., Hinds, D.A., Hyde, C.L., Warnes, G.R., Gomez Perez, F.J., Frazer, K.A., Elliott, P., Scott, J., et al. "Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides." Nat. Genet. 40 (2008): 149–151.
[2] Manolio, T. A., et al. "A HapMap harvest of insights into the genetics of common disease." Journal of Clinical Investigation, vol. 118, 2008, pp. 1590–605.
[3] Kastelein, J. J., et al. "Seven lipoprotein lipase gene polymorphisms, lipid fractions, and coronary disease: A HuGE association review and meta-analysis." American Journal of Epidemiology, vol. 168, 2008, pp. 1233–46.
[4] Wallace, C. "Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia." Am J Hum Genet, vol. 82, 2008, pp. 139–149.
[5] Kathiresan, S., et al. "Common variants at 30 loci contribute to polygenic dyslipidemia." Nat Genet, vol. 40, no. 12, 2008, pp. 1421-1428.
[6] Willer, C.J., et al. "Newly identified loci that influence lipid concentrations and risk of coronary artery disease." Nat Genet, vol. 40, no. 2, 2008, pp. 189-197.
[7] Aulchenko, Y.S., et al. "Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts." Nat Genet, vol. 40, no. 12, 2008, pp. 1406-1411.
[8] Burkhardt, R., et al. "Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13." Arterioscler Thromb Vasc Biol, 2008.
[9] Yuan, X., et al. "Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes." Am J Hum Genet, vol. 83, no. 2, 2008, pp. 265-274.
[10] Gieger, C., et al. "Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum." PLoS Genet, vol. 4, no. 11, 2008, e1000282.
[11] Schadt, E.E., Molony, C., Chudin, E., Hao, K., Yang, X., Lum, P.Y., Kasarskis, A., Zhang, B., Wang, S., Suver, C., et al. (2008). Mapping the genetic architecture of gene expression in human liver. PLoS Biol. 6, e107.
[12] Yoshida, K., et al. "Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase." J. Lipid Res., vol. 43, no. 10, 2002, pp. 1770–1772.
[13] Aulchenko, Y.S., et al. "Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts." Nat Genet, vol. 41, no. 1, 2009, pp. 47–55.
[14] Aalto-Setala, K., et al. "Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles." J. Clin. Invest., vol. 90, no. 5, 1992, pp. 1889–1900.
[15] Moldes, M., et al. "Adiponutrin gene is regulated by insulin and glucose in human adipose tissue." Eur. J. Endocrinol., vol. 155, 2006, pp. 887–895.
[16] Hayhurst, G.P., et al. "Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis." Mol. Cell. Biol., vol. 21, no. 4, 2001, pp. 1393–1403.
[17] Shih, D.Q., et al. "Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism." Nat. Genet., vol. 27, no. 4, 2001, pp. 375–382.
[18] Murphy, C., et al. "Regulation by SREBP-2 defines a potential link between isoprenoid and adenosylcobalamin metabolism." Biochem Biophys Res Commun, vol. 355, no. 2, 2007, pp. 359–364.
[19] Ridker, P.M., et al. "Loci related to metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study." Am J Hum Genet, vol. 82, no. 5, 2008, pp. 1185–1192.
[20] Vasan, R.S., et al. "Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study." BMC Med Genet, vol. 8, 2007, p. 57.
[21] Sirtori, C.R., et al. "A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity." Proc. Natl. Acad. Sci. USA, vol. 88, no. 11, 1991, pp. 4855–4859.
[22] Isaacs, A., et al. "The -514C->T hepatic lipase promoter region polymorphism and plasma lipids: a meta-analysis." J. Clin. Endocrinol. Metab., vol. 89, no. 8, 2004, pp. 3858–3863.
[23] Walli, A.K., and D. Seidel. "Role of lipoprotein-X in the pathogenesis of cholestatic hypercholesterolemia. Uptake of lipoprotein-X and its effect on 3-hydroxy-3-methylglutaryl coenzyme A reductase and acyl coenzyme A: cholesterol acyltransferase." J Lipid Res, vol. 24, no. 12, 1983, pp. 1660-1667.
[24] Buch, S., et al. "A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease." Nat. Genet., vol. 39, no. 8, 2007, pp. 995–999.